Literature DB >> 8984029

Antineutrophil cytoplasmic antibodies in sera from colectomised ulcerative colitis patients and its relation to the presence of pouchitis.

M Esteve1, J Mallolas, J Klaassen, A Abad-Lacruz, F González-Huix, E Cabré, F Fernández-Bañares, X Bertrán, E Condom, J Martí-Ragué, M A Gassull.   

Abstract

BACKGROUND: Few studies have evaluated the influence of colectomy on antineutrophil cytoplasmic antibody (ANCA) positivity in ulcerative colitis (UC). In small series of patients it has been suggested that ANCA positivity in UC might be predictive for development of pouchitis after colectomy. AIMS: To assess the prevalence of ANCA in UC patients treated by colectomy and a Brooke's ileostomy (UC-BI) or ileal pouch anal anastomosis (UC-IPAA), and the relation between the presence of ANCA, the type of surgery, and the presence of pouchitis.
SUBJECTS: 63 UC patients treated by colectomy (32 with UC-BI and 31 with UC-IPAA), 54 UC, and 24 controls.
METHODS: Samples were obtained at least two years after colectomy. ANCA were detected by indirect immunofluorescent assay.
RESULTS: There were no differences between patients with (36.3%) or without pouchitis (35.0%) and between patients with UC (55%), UC-BI (40.6%), and UC-IPAA (35.4%). However, ANCA prevalence significantly decreases in the whole group of operated patients (38.0%) compared with non-operated UC (p = 0.044).
CONCLUSIONS: The prevalence of ANCA in operated patients was significantly lower than in non-operated UC, suggesting that it might be related either to the presence of inflamed or diseased tissue. ANCA persistence is not related to the surgical procedure and it should not be used as a marker for predicting the development of pouchitis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8984029      PMCID: PMC1383198          DOI: 10.1136/gut.38.6.894

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  23 in total

1.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

2.  A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease.

Authors:  A Saxon; F Shanahan; C Landers; T Ganz; S Targan
Journal:  J Allergy Clin Immunol       Date:  1990-08       Impact factor: 10.793

3.  Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis.

Authors:  R H Duerr; S R Targan; C J Landers; N F LaRusso; K L Lindsay; R H Wiesner; F Shanahan
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

4.  Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses.

Authors:  R H Duerr; S R Targan; C J Landers; L R Sutherland; F Shanahan
Journal:  Gastroenterology       Date:  1991-06       Impact factor: 22.682

5.  An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir.

Authors:  R L Moskowitz; N A Shepherd; R J Nicholls
Journal:  Int J Colorectal Dis       Date:  1986-07       Impact factor: 2.571

Review 6.  The clinical relevance of ANCA in vasculitis.

Authors:  W L Gross; S Hauschild; N Mistry
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

7.  Is p-ANCA in ulcerative colitis directed against beta-glucuronidase?

Authors:  K Kaneko; Y Suzuki; Y Yamashiro; K Yabuta
Journal:  Lancet       Date:  1993-01-30       Impact factor: 79.321

8.  Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment.

Authors:  M Oudkerk Pool; P M Ellerbroek; B U Ridwan; R Goldschmeding; B M von Blomberg; A S Peña; K M Dolman; H Bril; W Dekker; J J Nauta
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

Review 9.  ANCA and associated diseases: immunodiagnostic and pathogenetic aspects.

Authors:  W L Gross; W H Schmitt; E Csernok
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

10.  Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis.

Authors:  W J Sandborn; C J Landers; W J Tremaine; S R Targan
Journal:  Am J Gastroenterol       Date:  1995-05       Impact factor: 10.864

View more
  6 in total

Review 1.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

2.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

3.  Experimental colitis induced by trinitrobenzenesulfonic acid: an ultrastructural and histochemical study.

Authors:  M I Torres; M García-Martin; M I Fernández; N Nieto; A Gil; A Ríos
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

Review 4.  Review article: the pathogenesis of pouchitis.

Authors:  K M Schieffer; E D Williams; G S Yochum; W A Koltun
Journal:  Aliment Pharmacol Ther       Date:  2016-08-24       Impact factor: 8.171

5.  Psychobiological subtypes of ulcerative colitis: pANCA status moderates the relationship between disease activity and psychological distress.

Authors:  Robert G Maunder; Gordon R Greenberg; Jonathan J Hunter; William J Lancee; A Hillary Steinhart; Mark S Silverberg
Journal:  Am J Gastroenterol       Date:  2006-10-04       Impact factor: 10.864

6.  Antineutrophil antibodies associated with ulcerative colitis interact with the antigen(s) during the process of apoptosis.

Authors:  J Mallolas; M Esteve; E Rius; E Cabré; M A Gassull
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.